Title: New onset of diabetes mellitus among patients on statin therapy among patients an outpatient clinic in Andkhoy, Afghanistan.

Biography:

Mohammad Shoaib Hamrah received his MD degree from Kabul Medical Institute, Afghanistan. He completed his Master’s in Healthcare Administration from Nagoya University Graduate Schoolof Medicine. He holds a PhD in  cardiology from the same university. He joined as head of Qarmqul Mother Child Clinic in Afghanistan in 1992.He also worked as an internist at Andkhoy District Hospital in Afghanistan. He joined as head of Internal Medicine Department at Andkhoy Hospital in Afghanistan.

Abstract

Statement of the Problem: Statins are the best-known and most widely used cholesterol lowering drugs around the world. Statins decrease cardiovascular morbidity and mortality in patients with and without ischemic heart disease. Statins are generally well tolerated by most patients. However, some adverse effects are associated with this group of medications. Recently, interest has been raised on the risk of new-onset of diabetes mellitus with statin treatment. In 2012, the US Food and Drug Administration has made new safety label changes for cholesterol-lowering statins concerning increased risk of haemoglobin A1 c (HB A1c) and fasting blood sugar. This study was conducted to investigate the association between statins and the incidence of new onset of diabetes among patients treated with statins in an outpatient clinic in Andkhoy, Afghanistan.

Methodology & Theoretical Orientation: The study was performed in an outpatient clinic in Andkhoy, Afghanistan. The case subjects included patients aged 40 years and above without diabetes who started statin therapy from Jan 2016 to December 2016. Patients with established diabetes before the start of statin therapy were excluded. 

Findings: In total 270 patients were investigated. Of these, 95 were statin users and 175 nonstatin users. The incidence rates of new onset of diabetes were 15% and 2.6% in the statin users and non statin users, respectively. The risk of new onset of diabetes among statin users (HR 1.9, 95% confidence interval(CI) I 1.0-3.9).Conclusion & Significance: t is concluded that all statin treatment is associated with an increased risk of NODM in in an outpatient clinic in Andkhoy, Afghanistan. Therefore, the screening for diabetes mellitus is needed among patients under treatment with statins.